JP2013533227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533227A5
JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
Authority
JP
Japan
Prior art keywords
ethoxy
fgf21
acetylamino
des181
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013513645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533227A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/057986 external-priority patent/WO2010142665A1/en
Application filed filed Critical
Priority claimed from PCT/EP2011/059273 external-priority patent/WO2011154349A2/en
Publication of JP2013533227A publication Critical patent/JP2013533227A/ja
Publication of JP2013533227A5 publication Critical patent/JP2013533227A5/ja
Withdrawn legal-status Critical Current

Links

JP2013513645A 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体 Withdrawn JP2013533227A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/EP2010/057986 WO2010142665A1 (en) 2009-06-11 2010-06-08 Glp-1 and fgf21 combinations for treatment of diabetes type 2
EPPCT/EP2010/057986 2010-06-08
CN2010/001099 2010-07-21
CN2010001099 2010-07-21
US37329010P 2010-08-13 2010-08-13
US61/373,290 2010-08-13
PCT/EP2011/059273 WO2011154349A2 (en) 2010-06-08 2011-06-06 Fgf21 analogues and derivatives

Publications (2)

Publication Number Publication Date
JP2013533227A JP2013533227A (ja) 2013-08-22
JP2013533227A5 true JP2013533227A5 (enExample) 2014-07-24

Family

ID=49179102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513645A Withdrawn JP2013533227A (ja) 2010-06-08 2011-06-06 Ｆｇｆ２１類似体および誘導体

Country Status (2)

Country Link
JP (1) JP2013533227A (enExample)
WO (1) WO2011154349A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
KR20150006059A (ko) * 2012-06-11 2015-01-15 일라이 릴리 앤드 캄파니 섬유모세포 성장 인자 21 변이체
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201504815QA (en) 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
WO2015103782A1 (en) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Fgf21 mutant and conjugate thereof
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
HUE044783T2 (hu) 2014-12-23 2019-11-28 Novo Nordisk As FGF21 származékok és alkalmazásaik
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017180988A2 (en) * 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
EP3463427A4 (en) * 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
WO2017220706A1 (en) 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108619490A (zh) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
AU2018256256B2 (en) 2017-04-21 2023-02-23 Yuhan Corporation Method for producing dual function proteins and its derivatives
CN111050786A (zh) 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
IL275499B2 (en) 2017-12-22 2024-03-01 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021142143A1 (en) 2020-01-08 2021-07-15 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
EP4192495A1 (en) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4337681A1 (en) * 2021-05-11 2024-03-20 Cytoki Pharma ApS Therapeutic derivatives of interleukin-22
AU2022341345A1 (en) 2021-09-08 2024-03-28 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
MX2007002616A (es) 2004-09-02 2007-05-16 Lilly Co Eli Muteinas de factor de crecimiento de fibroblasto 21.
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2358749B1 (en) * 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
ES2692495T3 (es) * 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2

Similar Documents

Publication Publication Date Title
JP2013533227A5 (enExample)
JP2018505146A5 (enExample)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
MX2011007544A (es) Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
JP2012529463A5 (enExample)
MY174002A (en) Combination theraphy for the treatment of diabetes
UA114700C2 (uk) Тверда фармацевтична форма для перорального застосування та процес її виготовлення
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2013530974A5 (enExample)
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
JP2015513544A5 (enExample)
HRP20140480T1 (hr) Pegilirani spojevi inzulina lispro
EA201100969A1 (ru) Солевые формы органического соединения
WO2009033770A3 (en) Calcitonin c-terminal flanking peptide for use as a therapeutic agent
WO2009033793A3 (en) Pentagastrin as a therapeutic agent
TNSN07447A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
WO2009033667A3 (en) Use of a peptide as a therapeutic agent
WO2009046822A3 (en) Use of the peptide ymdgtmsqv as a therapeutic agent
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
ATE495747T1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
JP2017508741A5 (enExample)
JP2011046708A5 (enExample)
WO2009046858A3 (en) Therapeutic uses of kisspeptin 13 and compositions thereof
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения